Education
About Us
Working with TipRanks
Follow Us
Synlogic (SYBX)
NASDAQ:SYBX
SYBX Stock Chart & Stats
$1.30
$0.02(1.41%)
At close: 4:00 PM EST
$1.30
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.90 - $1.96
Previous CloseN/A
Volume234.00
Average Volume (3M)41.08K
Market Cap
$16.61M
Enterprise Value$4.96M
Total Cash (Recent Filing)$15.59M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,698,919
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.34
Price to Sales (P/S)2134.34
P/FCF Ratio-0.54
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.90 and its highest was $1.96 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $16.61M.
When is Synlogic’s upcoming earnings report date?
Synlogic’s upcoming earnings report date is Nov 06, 2025 which is 28 days ago.
How were Synlogic’s earnings last quarter?
Synlogic released its earnings results on Aug 07, 2025. The company reported -$0.043 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.043.
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,698,919 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Synlogic reported an EPS of -$0.043 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.235%.
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
Company Description
Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
0.37% Insiders
2.36% Mutual Funds
53.47% Other Institutional Investors
42.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---